Home > Boards > Free Zone > Health and Sciences > Biotech Values

Recall Merck also tried to get an "improved

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
genisi Member Profile
 
Followed By 31
Posts 5,102
Boards Moderated 0
Alias Born 05/24/06
160x600 placeholder
Imf Cuts U.s. 2014 Growth Forecast To 1.7%
The International Monetary Fund revised its growth outlook for the U.S. economy for the second time in two months after a first-quarter contraction turned out to be worse than the fund originally forecast.
More Top Equities Stories Of The Day
Crash Investigators Face Difficult Task in Ukraine
European Stocks Slip; Shire Leads FTSE Gains
Have Big-Screen Smartphones Crashed the Tablet Party?
ADR Shares End Mixed; GlaxoSmithKline Shares Trade Actively
Taiwan Export Orders Point to Stronger Global Demand
Judge Delays Decision on Argentine Bonds
U.S. Hot Stocks: Hot Stocks to Watch
Alstom Orders Double but Sales Fall
genisi   Wednesday, 04/27/11 03:49:51 AM
Re: biomaven0 post# 118902
Post # of 180668 
Recall Merck also tried to get an "improved niacin" by targeting the same receptor with MK-0354, which despite significant decreases in FFAs levels and absence of flushing failed to demonstrate effects on HDL/LDL-Cholesterol and TGs in phase II. Obviously, being a GPR109A receptor agonist isn't all.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist